A BST R A C T Metabolic clearance rates and production rates of human luteinizing hormone (HLH) were determined in pre-and postmenopausal women by the constant infusion technique.
INTRODUCTION
Most of the information available on human gonadotropin physiology has been derived from bioassay data on extracts of large volumes of plasma or urine. The quantity of these fluids required for bioassay has prevented sequential studies at short intervals in a single patient. The recent lreparation of highly purified human luteinizing hormone (HLH) (1) and the development of a sensitive radioimmunoassay (2) with which HLH can be easily quantified in small samples of plasma or serum have now made it possible to estimate the pituitary secretion or production rate (PR) of 
HLH.
The purpose of the present study was to estimate the PR of HLH using the plasma clearance of HLH-131I and the endogenous plasma HLH level. Initial studies on plasma HLH-131I levels after a single injection showed a rapid multiexponential disappearance curve, never quite reaching a clearly linear slope during the time HLH-1311 blood levels could be reliably determined. Therefore, we have utilized the constant infusion (to equilibrium) method of Tait (3, 4) to estimate the metabolic clearance rate (MCR) or HLH-_311 from plasma.
METHODS
Preparation of HLH-'I3. Highly purified HLH (1) was labeled to specific activities of 50-150 Ac/lsg with 'I by a modification of the method of Greenwood et al. (5) . Exposure of the hormone to Chloramine T was limited to 15-20 sec before addition of sodium metabisulfite to avoid unnecessary damage to the hormone. HLH-13I at these specific activities contains about one 13"I atom per five molecules of HLH. The relative abundance of "31I per total iodide in so-called "carrier-free '8I"'1 has been found to range from 5 to 44%o (6) . Therefore, the ratio of total iodide atoms to HLH molecules was about 1:1. Immediately after iodination the mixture was passed through a Sephadex G-75 column. The fraction selected for studies showed essentially no damaged HLH-uI or free 'I by hydrodynamic flow chromatoelectrophoresis on Whatman 3 MM paper (Fig. 1) . The HLH-1'I was sterilized by Millipore filtration, cultured, and pyrogen tested. The interval between iodination and testing was 2-5 days.
Measurement of HLH-131I. HLH-'31I was precipitated from plasma or solution by a double antibody system (7) . Aliquots of 1 ml were treated with excess rabbit anti-HLH at 4VC for 24 hr. A sheep anti-rabbit globulin was added in excess, and the mixture was incubated for an additional 24 hr. The samples were centrifuged, and the supernatant was removed by suction. Total and precipitated radioactivity were determined on duplicate aliquots in a well-type scintillation counter. Greater than 97%o of the fraction used for studies was precipitable in a double antibody system with excess antibody on the day of iodination.
Measurement of endogenous HLH. Plasma HLH was determined by radioimmunoassay as previously described (2) .
Plasma HLH disappearance studies. Preliminary studies were performed to determine the feasibility of using the disappearance curve of HLH-9lI from plasma after a single injection to determine the MCR and PR of HLH. The disappearance of total and antibody precipitable radioactivity from plasma after a single bolus injection of HLH-'I was investigated in four patients: three with chromophobe adenomas (a 45 yr old woman, a 62 yr old woman, and a 44 yr old man) and a 40 yr old woman with carcinoma of the breast. All patients were given five drops of saturated potassium iodide solution every 6 hr for 24 hr before study to inhibit 1"1I uptake by the thyroid. 12 Continuous I-ILH-L'3I infusion studies. rhree groups of subjects were used for these studies: (a) five normal premenopausal women studied at random times during the menstrual cycle; (b) five normal premenopausal women taking norethinodrel and mestranol (5 mg daily on day 1 through 20 of cycle) for contraceptive purposes; and (c) four postmenopausal women. The latter group included two normal women and two women with carcinoma of the breast with no evidence of extensive hepatic or other metastases at the time of study. The subjects were again prepared with five drops of saturated potassium iodide every 6 hr for 24 hr before study. The infusion tests were initiated between 6 :00 and 10 :00 a.m. with the subjects fasting and at bed rest. A 10 ml heparinized sample of blood was drawn immediately before the test for endogenous HLH determination. A total dose of 5-25 Ac of HLH-'31I containing 0.8-3.2 U of HIM was given to each subject. One-fifth of the total (lose was given directly intravenously as a priming (lose 20 min before starting the infusion. The remainder of the HLH-"'I was infused in a 1% albumin solution in saline at a constant rate of 1.25-1.30 ml/min over a 3-6 hr period. HLH-'31I in the infusion solution did not change throughout the test. 10-ml heparinized blood samples were drawn every 20-30 min for the last 2 hr of the infusion (Fig. 2) . Four or more samples were used to calculate the mean plasma HLH-w1I at equilibrium. As a control for nonspecific degradation of HLH-'I by plasma, the HLH-'I was placed in plasma and incubated at 370C. The loss of immunoreactivity was less than 2% from 0 to 6 hr and was only 5% at 24 hr.
The plasma MCR defined as the volume of blood cleared completely and irreversibly of HLH-1"I in unit time was calculated after the method of Tait (3, 4) Table I . Although the MCR and PR could be calculated by the single injection technique, the disappearance curve of HLH-'31I was complex, and the area under the curve had to be mechanically or numerically integrated. Therefore, the constant infusion technique was used for subsequent studies. The disappearance curve of endogenous HLH from the plasma of the patient during hypophysectomy was not entirely satisfactory because blood was given to the patient during the procedure. However, before blood administration, the HLH Table II . In only one subject (subject 3) was there greater than 5% variation of any sample from the mean during the last hour of infusion. To further examine for evidence that equilibrium had been reached, the plasma HLH-131I levels were expressed as a per cent of the final concentration and inspected for the presence of an upward or downward trend. Only subject 3 continued to show a slight upward trend of plasma HLH-131I levels over the last hour of infusion. However, her values appeared sufficiently near equilibrium to include with the others (see Table II ). The MCR's were: 24.4 ± 1. Another assumption necessary to validate production rate studies is that a steady state is maintained in regard to secretion and degradation of the endogenous hormone during the test period. The degradation of HLH-131I must reach a steady rate during the constant infusion studies. Studies of diurnal HLH variation have shown no significant change over the course of 24 hr in women except during the HLH surge at the time of ovulation.4 Therefore, it appears that steady rates of HLH production and degradation were probably maintained throughout the period of these studies. The possible exception is subject 4 who was apparently having an ovulatory HLH elevation.
The finding that plasma HLH-131I in humans did not have a linear disappearance rate on a semilogarithmic plot after a single injection is of interest. Disappearance curves in the literature for 181I-labeled insulin (9), glucagon (10), growth hormone (11), and thyrotropin (12) after a single injection appear to show an initial linear segment after a mixing period followed by a slower decline. These disappearance curves are in good agreement with the disappearance of appropriate unlabeled hormones in these studies. If a single compartment of distribution is assumed, fractional turnover rates can easily be calculated from these data. In the case of HLH, however, there appears to be a definite multiexponential disappearance curve. Although the disappearance curves of HLH-131I and unlabeled HLH again appear to be in good agreement in the one patient at hypophysectomy and in primates, the initial disappearance is not linear and the single compartment assumption cannot be made. A meaningful MCR in a multicompartmental system should be a function of the total integrated area under the disappearance 4Ross, G. T., W. D. Odell, and P. L. Rayford. Unpublished observations. curve. Highly complex curves are mathematically difficult to resolve and it becomes necessary to integrate mechanically or numerically the area nder the curve. The conltinuous infusion method (3, 4) provides a simple meanls of integrating the area under the disappearance curve and is a valid technique for determining the clearance rate in both single and multicompartmental systems.
Another possible interpretation of the disappearance curves after the single injections is that some damaged HLH-111I was present. Iodination of smaller peptides such as alpha MSH (13) and arginine vasopressin (14) can result in a slowing of the disappearance curve. However, proteins smaller than HLH such as insulin (9) , glucagon (10) , and growth hormone (11, 15) , or equivalent in size and composition, such as thyrotropin (12), can be lightly iodinated without significantly changing the disappearance curve. Furthermore, the fraction used for the present studies showed less than 1 % damaged HLH-l31I by chromatoelectrophoresis and only immunoreactive HLH-"'8I was used in determining the infusion rates. It is very possible that a small fraction of damaged HLH-'31I might result in the slow disappearance indicated by the late portion of the plasma HLH-131I curve after the single injection, at a time when most of the labeled hormone had already been degraded. However, the error in clearance determinations of such a small fraction would be almost negligible over the time period of the constant infusion method. We also have found that human menopausal gonadotropin with almost no FSH activity can be iodinated with 127I using Chloramine T, total iodide, and sodium metabisulfite in ratios proportional to those used for the present study with minimal or no loss of biologic LH potency as determined by the rat ventral prostate assay. 5 Tait (3, 4) has described the rationale for usinig the constant infusion-to-equilibrium method for determining the metabolic clearance rates of steroids.
This method has not previously been applied to polypeptide hormones, but is equally applicable when it can be shown that the labeled hormone behaves in an identical manner to the unlabeled hormone in the system under study. HLH secretion of the pituitary by using HLH-131I. If the labeled hormone is cleared from the plasma at the same rate as the endogenous hormone, the ratio of the rate of HLH-'31I infusion to the final plasnla HLH-1 31I level at equilibrium will be equivalent to the ratio of the secretion of endogenous HLH to the endogenous plasma HLH level. The similar MCR values found by the single injection and constant infusion techniques suggest that either may be used for MCR and PR determinations. However, the constant infusion technique provides some advantages over the single injection method. The area under the infusion curve is automatically integrated, and factors which influence the MCR can be followed in the same subject (3). The shorter time period for infusion of HLH-131I reduces nonspecific damage to the iodinated hormone which could result in spuriously low MCR and PR values.
The present data from the constant infusion studies clearly show that there is little difference in the MCR of HLH among three groups of subjects with rather markedly differing plasma HLH levels. The studies before and after ovariectomy in one patient also showed no change in MCR while the plasma HLH more than doubled. These findings indicate that the fluctuations noted in plasma HLH levels are the result of changes in the rate of HLH secretion rather than the rate of HLH clearance. Although subject 4 who had the lowest body surface area also had the lowest MCR, generally the MCR did not correlate (P > 0.05) with height, weight, or body surface area.
Ryan (16) has found that the HLH content in the pituitaries of five healthy young premenopausal women dying suddenly ranges from 0.162 to 2.209 mg of NIH-LH-S1 per pituitary (mean = 1.445) by the ovarian ascorbic acid depletion assay (17) . The HLH content in the pituitaries of four postmenopausal women was 1.191-5.462 mg of NIH-LH-S1 per pituitary (mean = 3.453). Rosemberg and Lewis (18) have found 1 mg of NIH-LH-S1 to be equivalent to 500 U of the 2nd International Reference Preparation of Human Menopausal Gonadotropin by the ovarian ascorbic acid depletion assay. The total pituitary HLH content, therefore, averaged about 725 U in the premenopausal and 1725 U in the postmenopausal women. If the HLH PR's were to be maintained at a relatively stable level for 24 hr as suggested from the lack of significant diurnal variation except during the ovulatory surge, the premenopausal women would have a secretion of about 500-1100 U/day, and the postmenopausal women would have a secretion of about 3500 U/day. These values would represent a one-to twofold turnover of total pituitary HLH content daily in both groups. This estimated daily pituitary turnover of HLH is similar to the value reported for human thyrotropin (12) and suggests that the secretion of both hormones is an extremely active process with a rather rapid turnover rate in the pituitary.
The amount of HLH-131I that could be precipitated from the urine in the present study was less than 0.1%o. This value would suggest a low renal clearance of undegraded HLH. However, although we have shown that the clearance of HLH-31I from plasma is similar to Unlabeled HLH, we have no evidence that the renal clearance of HLH-1311 is the same as unlabeled HLH. Keller (19) has found that the renal clearance of HLH by bioassay is between 0.03 and 0.26 ml/ min in postmenopausal women. When these values are compared to our total MCR's of 18.4-37.7 ml/min from the present study, it appears that less than 5%o of the total HLH production actually appears in the urine in the biologically active form. Becker and Albert (20) have reported that the normal values for urinary excretion of HLH by the rat ventral prostate assay (21) are from 0.21 to 0.43 mg equivalents of NIH-LH-S1
per 24 hr in premenopausal women and 2.1 mg equivalents of NIH-LH-S1 per 24 hr in postmenopausal women. After conversion to International Units, according to Rosemberg and Lewis (18) (x 62.5 for rat ventral prostate assay), the values for premenopausal women are 13.1-25 U/ 24 hr in premenopausal and 131.3 U/24 hr in postmenopausal women. Again, it would appear that less than 5%o of the total daily HLH production can be measured in the urine by bioassay. There is no reason to believe that the renal clearance of biologically active HLH is important to hormone activity. It is of interest that urinary gonadotropin values which have been clinically invaluable in the past have probably been derived from a very small fraction of the total HLH production.
